Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$64.70
-0.9%
$71.40
$64.69
$87.86
$80.56B0.197.35 million shs2.02 million shs
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$373.96
+0.2%
$386.26
$254.85
$403.76
$132.65B1.361.65 million shs75,405 shs
Medtronic plc stock logo
MDT
Medtronic
$79.07
-0.2%
$83.62
$68.84
$92.02
$104.99B0.766.19 million shs227,652 shs
Sanofi stock logo
SNY
Sanofi
$49.01
-0.7%
$47.65
$42.63
$56.26
$123.98B0.611.95 million shs232,889 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-2.70%-1.35%-9.86%-17.92%-22.06%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
-0.50%+0.13%-6.16%-0.44%+26.50%
Medtronic plc stock logo
MDT
Medtronic
-1.41%+0.08%-5.34%-8.42%-11.92%
Sanofi stock logo
SNY
Sanofi
+5.90%+8.75%-0.78%-1.56%-12.20%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
4.9992 of 5 stars
4.25.04.24.12.92.53.1
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
4.8266 of 5 stars
2.45.00.04.03.82.53.1
Medtronic plc stock logo
MDT
Medtronic
4.6682 of 5 stars
2.24.03.34.12.62.51.9
Sanofi stock logo
SNY
Sanofi
3.1055 of 5 stars
2.15.02.50.02.30.02.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.33
Hold$84.5730.71% Upside
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
2.76
Moderate Buy$396.175.94% Upside
Medtronic plc stock logo
MDT
Medtronic
2.40
Hold$94.9120.03% Upside
Sanofi stock logo
SNY
Sanofi
2.17
Hold$55.0012.22% Upside

Current Analyst Ratings

Latest MDT, GILD, SNY, and ISRG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/26/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
4/24/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeReduce ➝ Hold$69.00
4/19/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$105.00
4/19/2024
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$425.00 ➝ $435.00
4/19/2024
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$412.00 ➝ $421.00
4/19/2024
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$440.00 ➝ $436.00
4/19/2024
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$365.00 ➝ $375.00
4/17/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$81.00 ➝ $75.00
4/8/2024
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$420.00 ➝ $430.00
4/3/2024
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$428.00 ➝ $462.00
3/15/2024
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$420.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$27.12B2.97$8.63 per share7.50$18.26 per share3.54
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$7.12B18.62$5.41 per share69.15$39.60 per share9.44
Medtronic plc stock logo
MDT
Medtronic
$31.23B3.36$7.20 per share10.98$38.83 per share2.04
Sanofi stock logo
SNY
Sanofi
$46.61B2.66$6.72 per share7.29$31.81 per share1.54

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$5.67B$4.5014.388.901.2020.89%38.85%13.60%N/A
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$1.80B$5.5467.5064.924.8427.16%12.91%11.22%7/18/2024 (Estimated)
Medtronic plc stock logo
MDT
Medtronic
$3.76B$3.1425.1814.482.7513.00%13.71%7.81%5/23/2024 (Confirmed)
Sanofi stock logo
SNY
Sanofi
$5.84B$2.3620.7710.561.4112.56%27.47%16.07%N/A

Latest MDT, GILD, SNY, and ISRG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/23/2024N/A
Medtronic plc stock logo
MDT
Medtronic
$1.45N/A-$1.45N/AN/AN/A
4/25/2024Q1 2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-$1.49-$1.32+$0.17$0.70$6.36 billion$6.69 billion    
4/18/2024Q1 24
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$1.3990$1.50+$0.1010$0.81$1.87 billion$1.89 billion      
2/20/202401/31/2024
Medtronic plc stock logo
MDT
Medtronic
$1.26$1.30+$0.04$1.61$7.95 billion$8.09 billion    
2/6/2024Q4 23
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$1.76$1.72-$0.04$2.30$7.10 billion$7.12 billion    
2/1/2024Q4 2023
Sanofi stock logo
SNY
Sanofi
$0.94$0.89-$0.05$2.02$13.02 billion$11.76 billion

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.084.76%+3.32%68.44%9 Years
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
N/AN/AN/AN/AN/A
Medtronic plc stock logo
MDT
Medtronic
$2.763.49%+6.45%87.90%47 Years
Sanofi stock logo
SNY
Sanofi
$1.382.82%+3.79%58.47%2 Years

Latest MDT, GILD, SNY, and ISRG Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/26/2024
Sanofi stock logo
SNY
Sanofi
Annual$1.47802.98%5/9/20245/10/20246/6/2024
3/7/2024
Medtronic plc stock logo
MDT
Medtronic
quarterly$0.693.24%3/21/20243/22/20244/12/2024
2/1/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Quarterly$0.774.14%3/14/20243/15/20243/28/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1.08
1.43
1.27
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
N/A
5.55
6.53
Medtronic plc stock logo
MDT
Medtronic
0.46
2.30
1.71
Sanofi stock logo
SNY
Sanofi
0.19
1.27
0.87

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
83.67%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
83.64%
Medtronic plc stock logo
MDT
Medtronic
82.06%
Sanofi stock logo
SNY
Sanofi
10.04%

Insider Ownership

CompanyInsider Ownership
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.16%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
0.90%
Medtronic plc stock logo
MDT
Medtronic
0.30%
Sanofi stock logo
SNY
Sanofi
1.00%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
18,0001.25 billion1.24 billionOptionable
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
13,676354.71 million351.51 millionOptionable
Medtronic plc stock logo
MDT
Medtronic
95,0001.33 billion1.32 billionOptionable
Sanofi stock logo
SNY
Sanofi
86,0882.53 billion2.50 billionOptionable

MDT, GILD, SNY, and ISRG Headlines

SourceHeadline
Sanofi profit slips on generic competition and currency effectsSanofi profit slips on generic competition and currency effects
msn.com - April 26 at 2:35 AM
Sanofi (NASDAQ:SNY) Shares Gap Up to $46.61Sanofi (NASDAQ:SNY) Shares Gap Up to $46.61
marketbeat.com - April 25 at 4:49 PM
Tyler Technologies Shares Reach 52-Week High Following Strong 1Q EarningsTyler Technologies Shares Reach 52-Week High Following Strong 1Q Earnings
marketwatch.com - April 25 at 2:59 PM
Sanofi (SNY) Q1 2024 Earnings Call TranscriptSanofi (SNY) Q1 2024 Earnings Call Transcript
fool.com - April 25 at 2:59 PM
Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock UpSanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up
zacks.com - April 25 at 12:21 PM
AbbVie reports positive results from Rinvoq versus Dupixent studyAbbVie reports positive results from Rinvoq versus Dupixent study
msn.com - April 25 at 11:32 AM
Drugmaker Sanofis Strong Dupixent And Beyfortus Vaccine Sales Propel Q1 EarningsDrugmaker Sanofi's Strong Dupixent And Beyfortus Vaccine Sales Propel Q1 Earnings
benzinga.com - April 25 at 10:24 AM
SNY Stock Earnings: Sanofi Beats EPS, Beats Revenue for Q1 2024SNY Stock Earnings: Sanofi Beats EPS, Beats Revenue for Q1 2024
investorplace.com - April 25 at 9:15 AM
Sanofi jumps as Q1 key profit measure tops estimates; Citi reiterates BuySanofi jumps as Q1 key profit measure tops estimates; Citi reiterates Buy
ca.investing.com - April 25 at 7:00 AM
Sanofi Sales, Profit Beat ForecastsSanofi Sales, Profit Beat Forecasts
wsj.com - April 25 at 3:25 AM
Sanofi Q1 profit slips on generic competition, forex effectsSanofi Q1 profit slips on generic competition, forex effects
reuters.com - April 25 at 1:32 AM
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidancePress Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
globenewswire.com - April 25 at 1:30 AM
Sanofi to report earnings first-quarter earnings ThursdaySanofi to report earnings first-quarter earnings Thursday
wfmz.com - April 24 at 2:17 PM
Whats in Store for These 5 Pharma Bigwigs in Q1 Earnings?What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
zacks.com - April 24 at 10:21 AM
Sanofi Asks Banks to Pitch for $20 Billion OTC SpinoffSanofi Asks Banks to Pitch for $20 Billion OTC Spinoff
finance.yahoo.com - April 24 at 5:21 AM
Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder StudySanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study
zacks.com - April 23 at 1:06 PM
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopeniaPress Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
globenewswire.com - April 23 at 1:00 AM
Skyhawk’s latest biopharma collaboration is worth up to $1.8BSkyhawk’s latest biopharma collaboration is worth up to $1.8B
bizjournals.com - April 22 at 10:11 PM
Sanofi reportedly settles 4K Zantac cases for $100MSanofi reportedly settles 4K Zantac cases for $100M
seekingalpha.com - April 22 at 12:53 PM
Foundry Partners LLC Sells 33,690 Shares of Sanofi (NASDAQ:SNY)Foundry Partners LLC Sells 33,690 Shares of Sanofi (NASDAQ:SNY)
marketbeat.com - April 21 at 10:35 PM
Q2 2024 Earnings Estimate for Sanofi Issued By Leerink Partnrs (NASDAQ:SNY)Q2 2024 Earnings Estimate for Sanofi Issued By Leerink Partnrs (NASDAQ:SNY)
americanbankingnews.com - April 20 at 2:44 AM
Paramount’s Shares Surge Following Sony and Apollo’s Joint Bid; ISS Backs Berkshire Hathaway Director Re-election, and MoreParamount’s Shares Surge Following Sony and Apollo’s Joint Bid; ISS Backs Berkshire Hathaway Director Re-election, and More
msn.com - April 19 at 10:26 AM
Sanofi to Post Q2 2024 Earnings of $0.91 Per Share, Leerink Partnrs Forecasts (NASDAQ:SNY)Sanofi to Post Q2 2024 Earnings of $0.91 Per Share, Leerink Partnrs Forecasts (NASDAQ:SNY)
marketbeat.com - April 19 at 8:31 AM
Federated Hermes Inc. Has $85.40 Million Stake in Sanofi (NASDAQ:SNY)Federated Hermes Inc. Has $85.40 Million Stake in Sanofi (NASDAQ:SNY)
marketbeat.com - April 19 at 8:27 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Gilead Sciences logo

Gilead Sciences

NASDAQ:GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Intuitive Surgical logo

Intuitive Surgical

NASDAQ:ISRG
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
Medtronic logo

Medtronic

NYSE:MDT
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Sanofi logo

Sanofi

NASDAQ:SNY
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.